Results

1–10 of 82 results for Aflibercept

Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Effects of Time Since Diagnosis to Intravitreal Aflibercept Injection and Baseline BCVA on Outcomes in CRVO: Post Hoc Analysis of the COPERNICUS and GALILEO Trials
Dilsher S. Dhoot, MD
Annual Meeting Talks
2022
Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
Aflibercept Monotherapy vs Initial Bevacizumab Followed by Aflibercept if Needed for Treatment of Center-Involved Diabetic Macular Edema
Chirag D. Jhaveri, MD, FASRS
Annual Meeting Talks
2022
Phase IIIb TALON study of brolucizumab versus aflibercept in a matched treat-and-extend regimen to treat neovascular AMD: 32-week primary outcomes
Carl D. Regillo, MD
Annual Meeting Talks
2022
Prospective Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: One-Year Outcomes
Amy C. Schefler, MD FACS FASRS
Annual Meeting Talks
2022
The Impact of the COVID-19 Pandemic on Aflibercept and Ranibizumab Anti-VEGF Injections
Kapil Mishra, MD
On Demand Cases, Courses, and Papers
2021
Treatment Switch From Aflibercept to Ranibizumab Pre-filled Syringe in Canadian DME Patients in a Real-World Setting: The PRECISE Study
Michel R Giunta, MD
On Demand Cases, Courses, and Papers
2021
Aflibercept Versus Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
Hani Salehi-Had, MD
On Demand Cases, Courses, and Papers
2021